TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to
determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy
(HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab
(EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.